Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVLN

Avalyn Pharma Inc

May 29 • 04:00PM ET

28.78

+0.39 1.37 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: AAPG ABEO SPTX ABCL ABSI AARD ABOS ABVX ACET IVA

| Held by: VTI TMSL VXF VTWO VTWG TMED VTWV TNXT VTHR

Index	-	P/E	-	EPS (ttm)	-	Insider Own	66.90%	Shs Outstand	41.81M	Perf Week	1.30%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-2.11	Insider Trans	5.22%	Shs Float	13.84M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	5.99%	Short Float	4.06%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	33.62%	Inst Trans	42.75%	Short Ratio	0.83	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	15.68%	ROA	-	Short Interest	0.56M	Perf YTD	-2.41%
Book/sh	-	P/C	-	EPS next 5Y	11.80%	ROE	-	52W High	32.22 -10.69%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	25.05 14.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.19% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.94	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	1.02%	Beta	-	Target Price	59.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	0.85%	Rel Volume	0.40	Prev Close	28.39
Employees	50	LT Debt/Eq	-	Earnings	-	SMA200	0.85%	Avg Volume	673.61K	Price	28.78
IPO	Apr 30, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	268,101	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Initiated	Morgan Stanley	Overweight	$53
May-26-26	Initiated	Jefferies	Buy	$52
May-26-26	Initiated	Guggenheim	Buy	$80
May-26-26	Initiated	Evercore ISI	Outperform	$51

May-27-26 08:00AM	Avalyn to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-26 08:00AM	Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 (GlobeNewswire)
May-05-26 04:01PM	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference (GlobeNewswire) -5.64%
May-01-26 04:01PM	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

CEOMs. Lyn Baranowski

CFO & Chief Business OfficerMr. Douglas R. Carlson

Ph.D.Dr. Melissa Rhodes DABT

Chief Medical OfficerDr. Howard M. Lazarus M.D.

Senior Director of IR & Corporate CommunicationsMs. Cassie Saitow

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVLN

Avalyn Pharma Inc

Upgrade your Finviz experience